Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02112123 · ClinicalTrials.gov registry record · Phase 1
Icariin to Prevent Corticosteroid-related Memory Changes
A Phase 1 study of the Pharmacokinetic Profile of Icariin in Humans, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT02112123 is a Phase 1 study of the Pharmacokinetic Profile of Icariin in Humans that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 24 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02112123, a Phase 1 study of the Pharmacokinetic Profile of Icariin in Humans, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate the pharmacokinetic properties of icariin, an active ingredient in the over-the-counter supplement, Horny Goat Weed.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Matching placebo
- DRUG Icariin
Study Locations (1)
Texas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2014-04 |
| Est. Completion | 2016-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02112123
The ClinicalTrials.gov registry entry for NCT02112123 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with the Pharmacokinetic Profile of Icariin in Humans appearing as the primary indexed condition, and to 2 interventions - of which Matching placebo is the first listed.
NCT02112123 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT02112123 about?
NCT02112123 is a clinical study titled "Icariin to Prevent Corticosteroid-related Memory Changes". The purpose of this study is to investigate the pharmacokinetic properties of icariin, an active ingredient in the over-the-counter supplement, Horny Goat Weed.
What is the current status of trial NCT02112123?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2014-04. Estimated completion is 2016-12.
What conditions does trial NCT02112123 study?
This clinical trial studies the following conditions: the Pharmacokinetic Profile of Icariin in Humans.
What interventions are being tested in trial NCT02112123?
The interventions under investigation include: Matching placebo (DIETARY_SUPPLEMENT), Icariin (DRUG).
Who is sponsoring clinical trial NCT02112123?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02112123 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.